IMMUTEP LIMITED

Analyst Reco. Immutep Limited

Equities

IMM

AU000000IMM6

Market Closed - Australian S.E. Other stock markets 02:10:11 2024-05-03 am EDT			5-day change	1st Jan Change
0.435 ^AUD	+3.57%		+12.99%	+26.09%

May. 02	Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	CI
May. 02	Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canaccord Starts Immutep at Buy, Price Target is AU$1.00	Apr. 29	MT
Baird Initiates Immutep With Outperform Rating, $7 Price Target	23-08-03	MT
Maxim Group Adjusts Price Target on Immutep to $10 From $8, Keeps Buy Rating	23-05-18	MT
Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers	22-06-03	CI
AIPAC final data as expected: Phase III supported with maintaining a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)	21-11-11	PU
O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)	21-11-03	PU
Immutep : Ladenburg Thalman - New Age Immune Regulator; Initiate with a Buy Rating and $8.30 Price Target	21-08-03	PU
IMMUTEP : Ladenburg Thalmann Starts Immutep at Buy With $8.30 Price Target	21-08-03	MT
Immutep : Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 PT	21-07-16	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer